ECSP951511A - Fenoles neuroprotectores - Google Patents
Fenoles neuroprotectoresInfo
- Publication number
- ECSP951511A ECSP951511A ECSP951511A ECSP951511A EC SP951511 A ECSP951511 A EC SP951511A EC SP951511 A ECSP951511 A EC SP951511A EC SP951511 A ECSP951511 A EC SP951511A
- Authority
- EC
- Ecuador
- Prior art keywords
- hydrogen
- alzheimer
- disease
- pharmaceutically acceptable
- dementia
- Prior art date
Links
- 150000002989 phenols Chemical class 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- -1 8-azabicyclo (3.2.1) octanyl Chemical group 0.000 abstract 1
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000013016 Hypoglycemia Diseases 0.000 abstract 1
- 206010061216 Infarction Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 210000000748 cardiovascular system Anatomy 0.000 abstract 1
- 230000001010 compromised effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 abstract 1
- 230000007574 infarction Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 210000000278 spinal cord Anatomy 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
- 230000009529 traumatic brain injury Effects 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
El invento se refiere a compuestos de la fórmula (gráfico), o sus sales de adición de ácidos aceptables farmacéuticamente, en la que (a) R2 y R5 se toman separadamente y R1, R2, R3 y R4 son cada uno independientemente hidrógeno alquilo de (C1-C6), halo, CF3, OH y OR7 y R5, es metilo o etilo; o (b) R2 y R5 se toman juntos, formando un anillo de croman-4-pl; y R1, R3 y R4 son cada uno independientemente hidrógeno, alquilo de (C1-C6) halo, CF3, Oh y OR7; y R6 es un derivado de piperidinilo; pirrolidinilo u 8-azabiciclo (3.2.1) octanilo sustituido; con la salvedad de que (a) cuando R2 y R5 se tomen separadamente, al menos uno de R1, R2, R3 y R4 no sea hidrógeno; y (b) cuando R2 y R5 se tomen juntos, al menos uno de R1, R3 y R4 no sea hidrógeno; sus cpomposiciones farmacéuticas, y procedimientos de tratamiento de mamíferos que sufren de ataque súbito, trauma del cordón espinal, lesión cerebral traumática, demencia por infarto múltiple, enfermedades degenerativas del SNC, tales como enfermedad de Alzheimer, demencia senil del tipo de alzheimer, enfermedad de Huntington, enfermedad de Parkinson, epilepsia, esclerosis lateral amiotrofica dolor, demencia por SIDA, estados psicóticos,, adicciona fármacos, migraña, hipoglucemia, estados ansiolíticos, inconsistencia urinaria y un acontecimiento isquémico consecuencia de cirugía del SNC, cirugia a corazón abierto o cualquier procedimiento durante el cual la función del sistema cardiovascular está comprometida, con un compuesto de la fórmula (1) anterior o una de sus sales aceptables farmacéuticamente.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP951511 ECSP951511A (es) | 1995-08-18 | 1995-08-18 | Fenoles neuroprotectores |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ECSP951511 ECSP951511A (es) | 1995-08-18 | 1995-08-18 | Fenoles neuroprotectores |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP951511A true ECSP951511A (es) | 1997-07-28 |
Family
ID=42042155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP951511 ECSP951511A (es) | 1995-08-18 | 1995-08-18 | Fenoles neuroprotectores |
Country Status (1)
| Country | Link |
|---|---|
| EC (1) | ECSP951511A (es) |
-
1995
- 1995-08-18 EC ECSP951511 patent/ECSP951511A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4410320A1 (es) | Fenoles neuroprotectores antiisquemicos y bloqueadores de receptores de aminoacidos excitadores definidos por la formula | |
| CA2413424A1 (en) | Substituted bicyclic derivatives for the treatment of abnormal cell growth | |
| WO2004056786A3 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| YU30702A (sh) | Novi derivati benzoimidazola, korisni agensi protiv proliferacije | |
| MY124390A (en) | Substituted bicyclic derivatives useful as anticancer agents | |
| AR016604A1 (es) | Uso de compuestos derivados de eteres vinilicos heterociclicos, compuestos derivados de eteres vinilicos heterociclicos, un procedimiento para laelaboracion de dichos compuestos y medicamentos que contienen uno o mas compuestos derivados de eteres vinilicos heterociclicos | |
| BG105365A (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
| CA2303801A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| YU41103A (sh) | Farmaceutski preparati receptor agonista nmda | |
| CA2303764A1 (en) | Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists | |
| IL147771A0 (en) | Novel 2-decarboxy-2-phosphinico prostaglandin f analogs | |
| CA2326076A1 (en) | Novel macrolides | |
| CA2324343A1 (en) | C11 oxymyl and hydroxylamino prostaglandins useful as medicaments | |
| HUP9903632A2 (hu) | Neuraminsav vegyületek, azokat tartalmazó gyógyszerkészítmények és eljárás e készítmények előállítására | |
| MY121206A (en) | Aminobenzamide compounds for the treatment of neurodegenerative disorders | |
| CA2376876A1 (fr) | Nouveaux derives d'isoindoloindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| CA2378628A1 (fr) | Nouveaux derives d'indenoindolones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| IL117083A (en) | Pyridine and pyridazine derivatives processes for the production thereof and pharmaceutical compositions containing these compounds | |
| EP0473993A3 (en) | Novel peptide derivatives and their pharmaceutical use | |
| WO2001035938A3 (de) | Pharmakologisch aktive tetrahydrothiopyran-4-ol-derivate, verfahren zu ihrer herstellung und verwendung | |
| WO2023130008A8 (en) | Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid and derivatives thereof | |
| CA2270026A1 (en) | Substituted bicyclic derivatives for treating central nervous system disorders | |
| TH51656A (th) | 5-(2-เอธิล-2h-เตตราโซล-5-อิล)-1-เมธิล-1,2,3,6-เตตราไฮโดรไพริดีน |